Comparison of Two Ovarian Stimulation Protocols Among Women with Poor Response: A Randomized Clinical Trial

Overview

Journal Eur J Transl Myol

Publisher PagePress

Date 2022 Jul 7

PMID 35796739

Authors

Minoodokht Bavarsadkarimi

Sirous Omidi

Farinaz Shahmoradi

Zahra Heidar

Sahar Mirzaei

Affiliations

Soon will be listed here.

Abstract

This is a randomized controlled trial conducted in a tertiary referral fertility department. Participants were women with previous poor ovarian response undergoing in vitro fertilization. (IVF). One hundred and ninety-two women were randomized to the short GnRH agonist and antagonist regimens. The primary outcome was the number of oocytes retrieved. Secondary outcome measures were the number of embryos transferred, chemical and clinical pregnancy rate and live birth. The number of oocytes retrieved was higher with the gonadotrophin-releasing hormone (GnRH) antagonist regimen compared to the short agonist regimen (3.10 2.70 vs. 2.992.60), but there was no significant difference. The duration of stimulation and total gonadotropin dose were higher with short agonist regimens compared to antagonist regimens, with the latter being statistically significant (p < 0.001). The chemical pregnancy rate was 8.33 percent with the short agonist regimen and 7.29 percent with the antagonist regimen, with no statistically significant difference (p = 0.79). In terms of lower cycles cancelation and higher chemical pregnancy, short GnRH agonist regim is appropriate choice for poor responders.

References

Ferraretti A, La Marca A, Fauser B, Tarlatzis B, Nargund G, Gianaroli L . ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011; 26(7):1616-24. DOI: 10.1093/humrep/der092. View

Li X, Wang L, Lv F, Huang X, Wang L, Pan Y . The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: A systematic review and meta-analysis. Medicine (Baltimore). 2017; 96(12):e6443. PMC: 5371493. DOI: 10.1097/MD.0000000000006443. View

Kahraman K, Berker B, Atabekoglu C, Sonmezer M, Cetinkaya E, Aytac R . Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. Fertil Steril. 2008; 91(6):2437-44. DOI: 10.1016/j.fertnstert.2008.03.057. View

Ulug U, Ben-Shlomo I, Turan E, Erden H, Akman M, Bahceci M . Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles. Reprod Biomed Online. 2003; 6(4):439-43. DOI: 10.1016/s1472-6483(10)62164-5. View

Mohamed K, Davies W, Allsopp J, Lashen H . Agonist "flare-up" versus antagonist in the management of poor responders undergoing in vitro fertilization treatment. Fertil Steril. 2005; 83(2):331-5. DOI: 10.1016/j.fertnstert.2004.07.963. View

Sunkara S, Coomarasamy A, Faris R, Braude P, Khalaf Y . Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. Fertil Steril. 2013; 101(1):147-53. DOI: 10.1016/j.fertnstert.2013.09.035. View

Huirne J, Lambalk C . Gonadotropin-releasing-hormone-receptor antagonists. Lancet. 2001; 358(9295):1793-803. DOI: 10.1016/S0140-6736(01)06797-6. View

Huirne J, van Loenen A, Schats R, Mcdonnell J, Hompes P, Schoemaker J . Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: antide and hormone levels. Hum Reprod. 2004; 19(10):2206-15. DOI: 10.1093/humrep/deh357. View

Keay S, Liversedge N, Mathur R, Jenkins J . Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol. 1997; 104(5):521-7. DOI: 10.1111/j.1471-0528.1997.tb11525.x. View

10.

Siristatidis C, Basios G, Pergialiotis V, Vogiatzi P . Aspirin for in vitro fertilisation. Cochrane Database Syst Rev. 2016; 11:CD004832. PMC: 6463901. DOI: 10.1002/14651858.CD004832.pub4. View

11.

Garcia J, Jones G, Acosta A, Wright Jr G . Human menopausal gonadotropin/human chorionic gonadotropin follicular maturation for oocyte aspiration: phase II, 1981. Fertil Steril. 1983; 39(2):174-9. DOI: 10.1016/s0015-0282(16)46815-9. View

12.

Zhang X, Feng T, Yang J, Hao Y, Li S, Zhang Y . A flexible short protocol in women with poor ovarian response over 40 years old. J Ovarian Res. 2021; 14(1):3. PMC: 7786950. DOI: 10.1186/s13048-020-00761-1. View

13.

Cummins J, Yovich J, Edirisinghe W, Yovich J . Pituitary down-regulation using leuprolide for the intensive ovulation management of poor prognosis patients having in vitro fertilization (IVF)-related treatments. J In Vitro Fert Embryo Transf. 1989; 6(6):345-52. DOI: 10.1007/BF01138775. View

14.

Hugues J, Cedrin Durnerin I . Revisiting gonadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins. Hum Reprod Update. 1998; 4(1):83-101. DOI: 10.1093/humupd/4.1.83. View

15.

Akman M, Erden H, Tosun S, Bayazit N, Aksoy E, Bahceci M . Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod. 2001; 16(5):868-70. DOI: 10.1093/humrep/16.5.868. View

16.

Papamentzelopoulou M, Stavros S, Mavrogianni D, Kalantzis C, Loutradis D, Drakakis P . Meta-analysis of GnRH-antagonists versus GnRH-agonists in poor responder protocols. Arch Gynecol Obstet. 2021; 304(2):547-557. DOI: 10.1007/s00404-020-05954-z. View

17.

Schmidt D, Bremner T, Orris J, Maier D, Benadiva C, Nulsen J . A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders. Fertil Steril. 2005; 83(5):1568-71. DOI: 10.1016/j.fertnstert.2004.10.053. View

18.

Tazegul A, Gorkemli H, Ozdemir S, Aktan T . Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial. Arch Gynecol Obstet. 2008; 278(5):467-72. DOI: 10.1007/s00404-008-0620-9. View

19.

Malmusi S, La Marca A, Giulini S, Xella S, Tagliasacchi D, Marsella T . Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation. Fertil Steril. 2005; 84(2):402-6. DOI: 10.1016/j.fertnstert.2005.01.139. View

20.

Akman M, Erden H, Tosun S, Bayazit N, Aksoy E, Bahceci M . Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Hum Reprod. 2000; 15(10):2145-7. DOI: 10.1093/humrep/15.10.2145. View